Cogent Biosciences (COGT) Change in Account Payables (2017 - 2026)

Cogent Biosciences' Change in Account Payables history runs 10 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• In Q1 2026, Change in Account Payables rose 98.04% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at -$410000.0 (up 70.94% YoY), while the FY2025 annual figure was -$2.5 million, down 284.76% from the prior year.
• Change in Account Payables was $4.2 million for Q1 2026 at Cogent Biosciences, up from -$6.5 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $6.1 million in Q3 2024 to a low of -$6.6 million in Q2 2024.
• Historically, Change in Account Payables has averaged $603588.2 across 5 years, with a median of $787000.0 in 2023.
• The sharpest annual moves came in 2023 and 2024: Change in Account Payables surged 671.51% in 2023, then sank 487.29% in 2024.
• A 5-year view of Change in Account Payables shows it stood at $1.7 million in 2022, then sank by 55.0% to $787000.0 in 2023, then tumbled by 487.29% to -$3.0 million in 2024, then tumbled by 114.07% to -$6.5 million in 2025, then surged by 164.98% to $4.2 million in 2026.
• The last three Change in Account Payables figures came in at $4.2 million (Q1 2026), -$6.5 million (Q4 2025), and -$596000.0 (Q3 2025), per Business Quant data.